Selected Publications:
Mineral sunscreens not recommended by Consumer Reports: suggestions to improve the review process.
Varedi A, Wu TP, Klein SZ, Leachman SA, Grossman D.
J Amer Acad Dermatol. 2019; 80:832-833.
Current controversies in early-stage melanoma. II. Questions on management and surveillance.
Klapperich ME, Bowen GM, Grossman D.
J Amer Acad Dermatol. 2019; 80:15-25.
Current controversies in early-stage melanoma. I. Questions on incidence, screening and histologic regression.
Gardner LJ, Strunck JL, Wu YP, Grossman D.
J Amer A cad Dermatol. 2019; 80:1-12.
A novel CDKN2A variant p16(L117P) in a patient with familial and multiple primary melanomas.
Li C, Liu T, Liu B, Hernandez R, Facelli J, Grossman D.
Pigment Melanoma Cell Res. 2019; 10.1111.
Emerging applications of eyetracking technology in dermatology.
John KK, Jensen JD, King AJ, Pokharel M, Grossman D.
J Dermatol Sci. 2018; 91:117-123.
Aspirin suppresses PGEi and activates AMP kinase to inhibit melanoma cell motility, pigmentation and selective tumor growth in vivo.
Kumar D, Rahman H, Tyagi E, Liu T, Li C, Lu R, Lum D, Holmen SL, Maschek JA, Cox JE, YanBrocklin MW, and Grossman D.
Cancer Prev Res (Phila). 2018; 11:629-642. (Featured on cover)
Similar survival of patients with multiple vs. single primary melanomas based on Utah SEER data (1973-2011).
Grossman D, Farnham J, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright LA.
J Am Acad Dermatol. 2018; 79:238-244.
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D.
Melanoma Res. 2017; 27:477-484. PMC5583702
Loss of p16(INK4A) stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway.
Tyagi E, Liu B, Li C, Liu T, Rutter J, Grossman D.
Oncotarget. 2017; 8:55848-55862. (Priority Research Paper) PMC5593528
Do pattern-focused visuals improve skin self-examination performance? Explicating the visual skill acquisition model (VSAM).
John KK, Jensen JD, King AJ, Ratcliff CL, Grossman D.
J Health Communication. 2017; 22:732-742.
A phase II randomized placebo-controlled trial of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress in vivo.
Cassidy P, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman D.
Cancer Prev Res (Phila). 2017; 10:36-44. PMC5219848
Reduction in nevus biopsy rates in patients monitored by total body photography.
Truong A, Strazzulla L, March J, Boucher KM, Nelson KC, Kim CC, Grossman D.
J Am Acad Dermatol. 2016; 75:135-143.
A safe and efficient model for ultraviolet radiation-induced herpes simplex labialis.
Goodson A, Varedi A, Hull C, Grossman D.
Photodermatol Photoimmunol Photomed. 2015; 31:170-172.
Predictive value of biopsies suspicious for melanoma: Support for 6 mm criterion in the ABCD rule.
Soltani-Arabshahi R, Jones B, Florell SR, Hu N, Sweeney C, Grossman D.
J Am Acad Dermatol. 2015; 72:412-418.
Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma-in-situ.
Duffy KL, Truong A, Bowen GM, Andtbacka RHI, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D.
J Am Acad Dermatol. 2014; 71:835-838. PMC4167347
Aspirin and other NSAIDs as chemoprevention agents in melanoma.
Goodman J, Grossman D.
Cancer Prev Res (Phila). 2014; 7:557-564. PMC4049124
Survivin promotion of melanoma metastasis requires upregulation of α5 integrin.
McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman D.
Carcinogenesis. 2013; 34:2137-2144. PMC3765044
Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.
Jenkins NC, Jung J, Liu T, Wilde M, Holmen SL, Grossman D.
J Invest Dermatol. 2013; 133:1043-1051. PMC3594444
Role of melanin in melanocyte dysregulation of reactive oxygen species.
Jenkins NC, Grossman D.
Biomed Res Int. 2013; 2013:908797. PMC3600250
The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.
Duffy K, Grossman D.
J Am Acad Dermatol. 2012; 67:19-32. PMC3621132
The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.
Duffy K, Grossman D.
J Am Acad Dermatol. 2012; 67:1-18. PMC3625372
Role of the apoptotic and mitotic regulator survivin in melanoma.
McKenzie JA, Grossman D.
Anticancer Res. 2012; 32:397-404.
The p16(INK4A) tumor suppressor regulates cellular oxidative stress.
Jenkins NC, Liu T, Cassidy P, Leachman SA, Boucher KM, Goodson AG, Samadashwily G, Grossman D.
Oncogene. 2011; 30:265-274. PMC 3003740
Survivin enhances motility of melanoma cells by supporting Akt activation and α5 integrin upregulation.
McKenzie JA, Liu T, Goodson AG, Grossman D.
Cancer Res. 2010; 70:7927-7937.
Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma.
Goodson AG, Florell SR, Hyde M, Bowen GM, Grossman D.
Dermatol Surg. 2010; 36:1087-1098. PMC3025478
Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi.
Goodson AG, Florell SR, Boucher KM, Grossman D.
J Am Acad Dermatol. 2010; 62:591-6. PMC2886801
Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention.
Goodson AG, Cotter MA, Cassidy P, Wade M, Florell SR, Liu T, Boucher KM, Grossman D.
Clin Cancer Res. 2009; 15:7434-7440. PMC2787788
Strategies for early melanoma detection: Approaches to the patient with nevi.
Goodson AG, Grossman D.
J Am Acad Dermatol. 2009; 60:719-735. PMC2690513
Survivin repression by p53, Rb and E2F2 in normal human melanocytes.
Raj D, Liu T, Samadashwily G, Li F, Grossman D.
Carcinogenesis. 2008; 29:194-201. PMC2292458
N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice.
Cotter MA, Thomas J, Cassidy P, Robinette K, Jenkins N, Florell SR, Leachman S, Samlowski WE, Grossman D.
Clin Cancer Res. 2007; 13:5952-5958. PMC2409148
Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma.
Fuller SR, Bowen GM, Tanner B, Florell SR, Grossman D.
Dermatol Surg. 2007; 33:1198-1206. PMC2292405
Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo.
Cotter MA, Florell SR, Leachman SA, Grossman D.
J Invest Dermatol. 2007; 127:2469-2471. PMC2292406
Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation.
Florell SR, Thomas J, Grossman D.
J Cutan Pathol. 2007; 34:667-674. PMC2410209
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice.
Thomas J, Liu T, Cotter MA, Florell SR, Robinette K, Hanks AN, Grossman D.
Cancer Res. 2007; 67:5172-5178. PMC2292453
Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist.
Yan H*, Thomas J*, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM, Grossman D.
Oncogene. 2006; 25:6968-6974. PMC2292411 *Equal contribution
Activation of dual apoptotic pathways in human melanocytes and protection by survivin.
Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM, Leachman SA, Grossman D.
J Invest Dermatol. 2006; 126:2247-2256. PMC2292407
Proteolytic cleavage of Livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase.
Yan H*, Brouha B*, Liu T, Raj D, Biddle D, Lee R, Grossman D.
J Dermatol Sci. 2006; 43:189-200. PMC2292408 *Equal contribution
Keratinocyte apoptosis in epidermal development and disease.
Raj D, Brash DE, Grossman D.
J Invest Dermatol. 2006; 126:243-257. PMC2291295
UVB-induced apoptosis drives clonal expansion during skin tumor development.
Zhang W*, Hanks AN*, Boucher K, Florell SR, Allen SM, Alexander A, Brash DE, Grossman D.
Carcinogenesis. 2005; 26:249-257. PMC2292404 *Equal contribution
Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi.
Florell SR, Bowen AR, Hanks AN, Murphy KJ, Grossman D.
J Cutan Pathol. 2005; 32:45-49. PMC2292117
Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias.
Bowen AR, Hanks AN, Murphy KJ, Florell SR, Grossman D.
Am J Dermatopathol. 2004; 26:177-181. PMC2292412
Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells.
Liu T, Brouha B, Grossman D.
Oncogene. 2004; 23:39-48. PMC2292403
Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression.
Allen SM, Florell SR, Hanks AN, Alexander A, Diedrich MJ, Altieri DC, Grossman D.
Cancer Res. 2003; 63:567-572.
Apoptosis regulators and responses in human melanocytic and keratinocytic cells.
Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D.
J Invest Dermatol. 2003; 120:48-55.
Amifostine aminothiols and protection of keratinocyte apoptosis and DNA damage.
Diedrich MJ, Warters RL, Grossman D.
J Invest Dermatol. 2002; 119:707-708.
Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53.
Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC.
J Clin Invest. 2001; 108:991-999. PMC200956
Inhibition of melanoma tumor growth in vivo by survivin targeting.
Grossman D, Kim PJ, Schechner JS, Altieri DC.
Proc Natl Acad Sci USA. 2001; 98:635-640. PMC14640
Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.
Grossman D, Altieri DC.
Cancer Metastasis Rev. 2001; 20:3-11.
These publications can be downloaded for personal use and are not intended for redistribution.